Gamma-Aminobutyric acid

Clinical Research by Salem Anaesthesia Pain Clinic, Surrey, Canada, Shows That Clonidine is Better Than Zopiclone for Insomnia Treatment

Retrieved on: 
Wednesday, November 2, 2022
Patient safety, Health, Xerostomia, Gamma-Aminobutyric acid, Attention deficit hyperactivity disorder predominantly inattentive, Clonidine, Fatigue, Brain, Research, Hallucination, GLOBE, Hypertension, Drug, Insomnia, Safety, Nightmare, Anxiety, Amnesia, Bruxism, Journal, Patient, Mood disorder, Confusion, Benzodiazepine, Falls, Addiction, Headache, Depression, Chronic pain, Dentistry, Pharmaceutical industry

SURREY, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- A clinical research study has shown that Clonidine is better than Zopiclone for insomnia treatment in chronic pain patients.

Key Points: 
  • SURREY, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- A clinical research study has shown that Clonidine is better than Zopiclone for insomnia treatment in chronic pain patients.
  • The critically acclaimed research was led and authored by Dr. Olu Bamgbade at the Salem Anaesthesia Pain Clinic in Surrey, British Columbia, Canada.
  • Dr. Olu Bamgbade is the director of the Salem Anaesthesia Pain Clinic, a specialist pain clinic and research center( https://salempainclinic.net/ ).
  • Based in Surrey, British Columbia, Canada, Salem Anaesthesia Pain Clinic is aspecialist pain clinic and research center that provides multimodal pain management, interventional pain treatment, substance misuse therapy, insomnia treatment and preoperative optimization therapy.

ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy

Retrieved on: 
Wednesday, June 29, 2022
FDA, Assistant, Patient, Sarcocystis neurona, Biopsy, Gamma-Aminobutyric acid, Research, Brain, GLOBE, COVID-19, Growth, CNS, GABA, Company, U.S. Securities and Exchange Commission, Lists of diseases, Seizure, Therapy, State University of New York Upstate Medical University, Particular, Doctor of Philosophy, Neurosurgery, Nasdaq, Quality of life, Temporal lobe epilepsy, Solution, MD, Security (finance), Epilepsy, Pharmaceutical industry

An estimated three million Americans have epilepsy, and 25 to 35 percent live with ongoing seizures despite dozens of approved drugs on the market.

Key Points: 
  • An estimated three million Americans have epilepsy, and 25 to 35 percent live with ongoing seizures despite dozens of approved drugs on the market.
  • The first stage of the trial is an open-label dose-escalation study in up to 10 patients with MTLE.
  • Our team is proud to partner with Neurona to support their Phase 1/2 clinical trial of what could potentially be a breakthrough regenerative cell therapy for MTLE.
  • ClearPoint Neuro is partnered with approximately 45 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.

Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

Retrieved on: 
Wednesday, June 29, 2022
Cell, Neurosurgery, CIRM, Gamma-Aminobutyric acid, Patient, Brain, Regenerative medicine, GLOBE, Temporal lobe, GABA, Seizure, Lists of diseases, SAN, Neurology, California Institute for Regenerative Medicine, State University of New York Upstate Medical University, Clinical trial, GABAergic, Hippocampus, Temporal lobe epilepsy, Safety, Program, Work, Therapy, Epilepsy, Interneuron, Pharmaceutical industry, Sarcocystis neurona

SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, today announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epilepsy study. An estimated three million Americans have epilepsy, and 25 to 35 percent live with ongoing seizures despite dozens of approved drugs on the market, which means that there is a huge unmet medical need in this community. NRTX-1001 is a regenerative neural cell therapy delivered as a single dose and designed to provide long-term secretion of gamma-aminobutyric acid (GABA), a key inhibitory neurotransmitter, to repair hyper-excitable neural networks associated with mesial temporal lobe epilepsy (MTLE), the most common form of focal epilepsy in adults.

Key Points: 
  • We are very excited to take this next step, bringing a first-in-class, novel regenerative treatment to people living with chronic focal seizures.
  • We are delighted to work with the Neurona team to evaluate the potential of this exciting new therapeutic approach.
  • Neuronas multicenter, Phase 1/2 clinical trial is designed to evaluate the safety and efficacy of a single administration of NRTX-1001 for drug-resistant MTLE.
  • The first part of the clinical trial is supported by a recently announced $8.0 million grant from the California Institute for Regenerative Medicine (CIRM; CLIN2-13355).

Relaxium® Makes INC. Magazine's 5000 Fastest-Growing Private Companies in America as It's Helping Thousands of Americans Sleep Sound, Wake Up Refreshed

Retrieved on: 
Tuesday, November 9, 2021
GABA, Inc. (magazine), Insomnia, Clinical trial, CEO, Inc., Lists of diseases, Founder, Retail, Melatonin, Instagram, Multimedia, BOCA, United States Department of Veterans Affairs, Founder CEO, Air force, Gamma-Aminobutyric acid, United, Tuskegee Veterans Administration Medical Center, Pharmaceutical industry

Timea Ciliberti, Founder & CEO of Relaxium®, along with her husband, Dr. Eric Ciliberti, M.D., a distinguished Clinical Neurologist, Sleep Expert, and Founder of The American Behavioral Research Institute, developed it, saw the need for their safer, non-habit-forming sleep aid---and were unshakable and tenacious in their efforts to take Relaxium to the masses. It is no accident that Relaxium® is now trending as the hottest sleep aid product in the country and named in the top 10% of the fastest growing companies!

Key Points: 
  • It is no accident that Relaxium is now trending as thehottest sleep aid product in the country and named in the top 10% of the fastest growing companies!
  • "I'm proud of what our team has achieved so far in helping so many suffering from these common enemies, sleeplessness and mood disorders.
  • Our receiving this recognition inspires us even more to help everyone who is anxious and sleep-deprived in America," said developer of Relaxium, Dr. Ciliberti.
  • In fact, in a recent major clinical trial, Relaxium Sleep's formula proved to be safe and effective with falling asleep, staying asleep and awakening refreshed.

FAB CBD Celebrates Customers and Community on National CBD Day

Retrieved on: 
Thursday, August 5, 2021
Cream, Theanine, Industry, Organization, Science, Melatonin, Fab, Operation Underground Railroad, Gamma-Aminobutyric acid, National, Multimedia, Vanilla, Citrus, Feeding America, Online shopping, Coffee, Metal fabrication, Animal

MILWAUKEE, Aug. 5, 2021 /PRNewswire/ -- FAB CBD, headquartered in Milwaukee, WI, is celebrating National CBD Day in a big way this year .

Key Points: 
  • MILWAUKEE, Aug. 5, 2021 /PRNewswire/ -- FAB CBD, headquartered in Milwaukee, WI, is celebrating National CBD Day in a big way this year .
  • Through the brand's National CBD Sale, customers will receive a percentage off of their total order at checkout.
  • During the National CBD Sale, customers will receive the following discounts:
    As an added bonus, customers will receive free shipping on all orders over $99.
  • Ever since its founding back in 2017, FAB CBD has been laser-focused on pushing the envelope in the CBD industry by offering customers thoughtful, carefully crafted, cutting-edge CBD products.